ESPE Abstracts (2018) 89 P-P2-123

Allopurinol Ameliorates Non-Alcoholic Fatty Liver Disease in Rats

Huseyin Anil Korkmaza, Huseyin Aktugb, Dincer Atilac, Vatan Barisikd, Nur Arslane & Oytun Erbasb

aBalıkesir Atatürk State Hospital, Balikesir, Turkey; bEge University Faculty of Medicine, Izmir, Turkey; cIzmir Public Health Directorate, Izmir, Turkey; dMetropol Medicine Center, Izmir, Turkey; eDokuz Eylul University Faculty of Medicine, Izmir, Turkey

Background: Hyperuricemia has been found to be associated with non-alcoholic fatty liver disease (NAFLD).

Aim: The aim of this study was to evaluate whether allopurinol affects the course of experimental NAFLD in rats.

Study Design: Mature, albino Sprague Dawley rats were fed water containing 30% fructose without ethanol for up to 8 weeks. After demonstration of steatosis in the 8th week, either allopurinol or saline was administered daily.

Methods: Liver histopathological score was determined according to steatosis (the percentage of liver cells containing fat): <25%=1+, 25% - 50%=2+, 51% - 75%=3+, >75%=4+; inflammation and necrosis: 1 focus per low-power field =1+; and 2 or more foci=2+. The number of liver IL-1 and IL-2 positive cells was measured by systematically scoring at least 100 hepatocyte cells per field in 10 fields of tissue sections at a magnification of 100.

Results: Allopurinol group presented significant difference in xanthine oxidase (XO) activity and lipid peroxidation compared with saline treatment (XO; 0.098±0.006 mU/mg g vs. 0.162±0.008 mU/mg, P<0.05, 0.116±0.040 nmol MDA/mg g vs. 0.246±0.040 nmol MDA/mg, P<0.05). Allopurinol group had lower histopathological score, IL-1 and IL-2 immunoexpression in the liver than saline group (2.13±0.35 vs. 5.45±0.24, P<0.05, IL-1; 5.76±0.43 vs. 12.85±3.26, P<0.05, IL-2; 8.55±1.14 vs. 56.23±7.12, P<0.05).

Conclusions: Allopurinol ameliorates non-alcoholic fatty liver disease by reducing xanthine oxidase activity and lipid peroxidation.

Article tools

My recent searches

No recent searches.